Neurocrine Plans Indiplon Resubmission In Second Quarter ’07
This article was originally published in The Pink Sheet Daily
Executive Summary
The company will be seeking a new partner after the NDA for the insomnia agent is re-submitted.
You may also be interested in...
DOV Reclaims Rights To Triple Reuptake Inhibitors From Merck
DOV says it will seek “broad partnership opportunities” to develop two norepinephrine, serotonin and dopamine reuptake inhibitors for depression.
DOV Reclaims Rights To Triple Reuptake Inhibitors From Merck
DOV says it will seek “broad partnership opportunities” to develop two norepinephrine, serotonin and dopamine reuptake inhibitors for depression.
Neurocrine Delays Indiplon Resubmission To Run Confirmatory Trial
Adding an insurance study to the NDA package means Neurocrine could finally see income from the insomnia aid in late 2008.